Comparative potential of Simvastatin, Rosuvastatin and Fluvastatin against bacterial infection: an in silico and in vitro study
In the current investigation, we have compared the potential of statin drugs (Simvastatin, Rosuvastatin and Fluvastatin) as potential anti-bacterial agent by conducting in silico, in vitro and ex vivo studies. In silico study was conducted to check the interaction of statin drugs towards various targets of bacteria. The percentage growth retardation, bacterial growth kinetics, MIC determination, post antibiotic effect and biofilm formation assay were conducted to check the anti-bacterial effect of statin drugs under in vitro conditions. Finally, MTT assay was used to check the percentage of immune cell viability after Simvastatin treatment. Docking studies have revealed good interaction of Simvastatin, Rosuvastatin and Fluvastatin towards various targets of bacterial strains as that of the internal ligand. Simvastatin has shown good antibacterial activity against S. aureus, B. pumilus, P. aeruginosa and S. enterica as compared to Rosuvastatin and Fluvastatin. In vitro results have shown concentration and time dependent inhibition of bacterial growth by Simvastatin in concentration range of 64–256 μg/ml. Finally, MTT assay have shown non-cytotoxic effect of Simvastatin against adaptive immune system. In conclusion, Simvastatin could be a potential candidate as an anti-bacterial agent against a wide range of bacterial infections. However, further studies are required to check its complete role before starting phase I clinical trial.
KeywordsSimvastatin Rosuvastatin Fluvastatin Docking study Bacterial infections Antibiotics
Authors are thankful to Shri. Parveen Garg, Chairman, ISFCP, for providing research facility. Authors are thankful to Mr. Saurabh Bhandari, Assistant Professor, Microbiology Division, ISFCP, Moga for providing support in completion of this research work. Authors are also thankful to Mr. Anshul Ruhela, B.Tech., Ansal University, for graphic enhancement of images. Author, Anoop Kumar is also thankful to Dr. S.J.S. Flora, Director, NIPER, Raebareli for their constant support and motivation.
Compliance with ethical standards
Animal house is registered with the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India. Registration number: 816/Po/Re/S/04/CPCSEA.
Conflict of interest
This manuscript described has not been published before; not under consideration for publication anywhere else; and has been approved by all co-authors.
- Bannister RM, Wanderlay WC, Brew J (2010) Treatment of microbial infections. Biocopea Limited. U.S. Patent Application. 13/509:534Google Scholar
- Craig WA (1996) Post-antibiotic effect. Antibiotics in laboratory medicine, 4th edn. Williams and Wilkins Co., BaltimoreGoogle Scholar
- Davignon J, Jacob RF, Mason RP (2004) The antioxidant effects of statins. Coron Artery Dis 15:251–258. https://doi.org/10.1097/01.mca.0000131573.31966.34 CrossRefGoogle Scholar
- Grewal GK, Rawal RK (2014) Molecular docking studies on (hetero) arlylidene (4-substituted-thiazol-2-yl) hydrazines as MAO-B inhibitors. Asian J Biomed Pharm Sci 4:56Google Scholar
- Gupta M, Sharma R, Kumar A (2018a) Docking techniques in pharmacology: how much promising? Comput Biol Chem 76:210–217. https://doi.org/10.1016/j.compbiolchem.2018.06.005 CrossRefGoogle Scholar
- Jouneau S, Bonizec M, Belleguic C, Desrues B, Brinchault G, Galaine J (2011) Anti-inflammatory effect of fluvastatin on IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens in cystic fibrosis. PLoS ONE 6:22655. https://doi.org/10.1371/journal.pone.0022655 CrossRefGoogle Scholar
- Langfield RD, Scarano FJ, Heitzman ME, Kondo M, Hammond GB, Neto C (2004) Use of a modified microplate bioassay method to investigate antibacterial activity in the Peruvian medicinal plant Peperomiagalioides. J Ethnopharmacol 94:279–281. https://doi.org/10.1016/j.jep.2004.06.013 CrossRefGoogle Scholar
- Lefer DJ (2011) Statins as potent anti-inflammatory drugs. Circ Res 106:2041–2042. https://doi.org/10.1161/01.CIR.0000033635.42612.88 CrossRefGoogle Scholar
- Mullin R (2014) Cost to develop new pharmaceutical drug now exceeds $2.5 B. Sci Am 24:1–2Google Scholar
- NCCLS (2006) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7eA7. Clinical and laboratory Standards Institute, WayneGoogle Scholar
- Stancu C, Sima A (2001) Statins: mechanism of action and effects. J Cell Mol Med 25:378–387. https://doi.org/10.1111/j.1582-4934.2001.tb00172.x CrossRefGoogle Scholar
- Tabish SA, Syed N (2015) The future of humanity and microbes: impact of emerging infectious diseases on global health and economies. Int J Pharm Sci Res 4:2427–2442Google Scholar
- Who G (2013) WHO methods and data sources for global burden of disease estimates 2000–2011. Department of Health Statistics and Information Systems, GenevaGoogle Scholar